机译:在II期研究中,在II期研究中使用90 90 ybritumomab Tiuxetan进行新诊断的高风险和中性风险卵泡淋巴瘤
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Department of Laboratory MedicineSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
Department of Laboratory MedicineSunnybrook Health Sciences CentreToronto ON Canada;
Department of Laboratory MedicineSunnybrook Health Sciences CentreToronto ON Canada;
Odette Cancer CentreSunnybrook Health Sciences CentreToronto ON Canada;
90Y ibritumomab tiuxetan; follicular lymphoma; radio‐immunotherapy;
机译:在II期研究中,在II期研究中使用90 90 ybritumomab Tiuxetan进行新诊断的高风险和中性风险卵泡淋巴瘤
机译:短程氟达拉滨,米托蒽醌,利妥昔单抗然后90y-ibritumomab替西坦治疗未经治疗的中/高危滤泡性淋巴瘤的II期临床试验
机译:短期疗程氟达拉滨,米托蒽醌,利妥昔单抗然后90Y-ibritumomab替西坦治疗未经治疗的中/高危滤泡性淋巴瘤的II期临床试验
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:美国20--90岁女性中与低骨矿物质密度和髋部骨折相关的危险因素(NHANES III研究)。
机译:中/高危滤泡性淋巴瘤中氟达拉滨米托蒽醌利妥昔单抗的90钇-ibritumomab替沙坦合并治疗:中位随访7年后更新了长期结果
机译:90- yttrium-ibritumomab Tiuxetan整合Fludarabine,Mitoxantrone,Rituximab中中间/高风险淋巴瘤:在7年的中位随访后更新了长期结果